KP372-1

KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) [1][2][3].

Product Specifications

CAS Number

[1374996-60-7]

UNSPSC

12352005

Hazard Statement

H302

Target

Akt; Apoptosis; Quinone Reductase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pdk1-akt-flt-inhibitor-1.html

Purity

99.5

Solubility

DMSO : 17.86 mg/mL (ultrasonic)

Smiles

O=C1C2=C(C3=NC4=NN=NN4N=C31)C=CC=C2.O=C5C6=NC7=NN=NN7N=C6C8=C5C=CC=C8

Molecular Formula

C20H8N12O2

Molecular Weight

448.36

Precautions

H302

References & Citations

[1]Mandal M, et al. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol. 2006 Apr;42 (4) :430-9.|[2]Zhao Y, et al. SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents. Cell Metab. 2015 May 5;21 (5) :777-89. |[3]Viera T, et al. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition. Sci Rep. 2020 Nov 19;10 (1) :20210.